LIRRH Trial for the Right-sided Colon Cancer

The aim of this clinical trial is to compare the short- and long-term outcomes of laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) with those of traditional laparoscopic right hemicolectomy (TRH) for ascending and proximal transverse colon cancer.

This is a prospective, single-center, open-label, randomized controlled clinical trial. Eligible patients will be randomly assigned (1:1) to undergo either LIRRH or TRH and will receive the corresponding surgical procedure. Primary endpoint: 3-year disease-free survival (DFS). Secondary endpoints: 1. Complications within 90 days postoperatively; 2. Pathology-related indicators, including positive margin rate, number of harvested lymph nodes, and lymph-node metastasis rate; 3. Assessment of postoperative intestinal microbiota changes; 4. 5-year overall survival (OS).